Ariane Jouve-Darut
Dijon, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer: the PRODIGE-13 FFCD phase III trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 02, 2025
Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: January 26, 2023
Long-term quality of life and sexual function of elderly people with endometrial or ovarian cancer.
Journal: Health and quality of life outcomes
Published: July 06, 2020
Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLD.
Journal: Journal of geriatric oncology
Published: October 29, 2019
Oxaliplatin-Induced Evans Syndrome: A Possible Dual Mechanism.
Journal: Clinical colorectal cancer
Published: April 15, 2019
Prognostic Factors of Survival among Women with Metastatic Breast Cancer and Impact of Primary or Secondary Nature of Disease on Survival: A French Population-Based Study.
Journal: The breast journal
Published: December 10, 2016
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.
Journal: Breast cancer research : BCR
Published: May 24, 2016
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients.
Journal: Oncotarget
Published: April 12, 2016
Last Updated: 09/26/2026